Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity

Christian Kellner; Stefanie Derer; Katja Klausz; Sophia Rosskopf; Tim Wirt; Thies Rösner; Anna Otte; Elisa Cappuzzello; Matthias Peipp

doi:10.1007/978-1-4939-8648-4_20

Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity

Christian Kellner, Stefanie Derer, Katja Klausz, Sophia Rosskopf, Tim Wirt, Thies Rösner, Anna Otte, Elisa Cappuzzello, Matthias Peipp^*

^*Corresponding author for this work

Clinic of Internal Medicine I

University of Kiel

2 Citations (Scopus)

Abstract

Monoclonal antibodies are established treatment options in cancer therapy. However, not all patients benefit from antibody therapy. Basic research and findings from clinical trials revealed that certain Fc-mediated effector mechanisms triggered by monoclonal antibodies are essential for efficient antitumor activity. Today, next-generation monoclonal antibodies can be designed displaying tailor-made improved effector functions. The introduction of Fc-engineering technologies offers the potential to fine-tune Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDC). Fc-engineered antibodies hopefully will overcome some limitations of current forms of antibody therapy.

Original language	English
Title of host publication	Antibody Engineering
Editors	Damien Nevoltris, Patrick Chames
Number of pages	17
Volume	1827
Place of Publication	New York, NY
Publisher	Humana Press Inc.
Publication date	09.09.2018
Pages	381-397
ISBN (Print)	978-1-4939-8647-7
ISBN (Electronic)	978-1-4939-8648-4
DOIs	https://doi.org/10.1007/978-1-4939-8648-4_20
Publication status	Published - 09.09.2018

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-4939-8648-4_20

Cite this

Kellner, C., Derer, S., Klausz, K., Rosskopf, S., Wirt, T., Rösner, T., Otte, A., Cappuzzello, E., & Peipp, M. (2018). Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity. In D. Nevoltris, & P. Chames (Eds.), Antibody Engineering (Vol. 1827, pp. 381-397). (Methods in Molecular Biology; Vol. 1827). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-8648-4_20

@inbook{ba220b4f281c4f0d81f8cf2eb5857b07,

title = "Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity",

abstract = "Monoclonal antibodies are established treatment options in cancer therapy. However, not all patients benefit from antibody therapy. Basic research and findings from clinical trials revealed that certain Fc-mediated effector mechanisms triggered by monoclonal antibodies are essential for efficient antitumor activity. Today, next-generation monoclonal antibodies can be designed displaying tailor-made improved effector functions. The introduction of Fc-engineering technologies offers the potential to fine-tune Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDC). Fc-engineered antibodies hopefully will overcome some limitations of current forms of antibody therapy.",

author = "Christian Kellner and Stefanie Derer and Katja Klausz and Sophia Rosskopf and Tim Wirt and Thies R{\"o}sner and Anna Otte and Elisa Cappuzzello and Matthias Peipp",

year = "2018",

month = sep,

day = "9",

doi = "10.1007/978-1-4939-8648-4_20",

language = "English",

isbn = "978-1-4939-8647-7",

volume = "1827",

series = "Methods in Molecular Biology",

publisher = "Humana Press Inc.",

pages = "381--397",

editor = "Nevoltris, {Damien } and Chames, {Patrick }",

booktitle = "Antibody Engineering",

}

Kellner, C, Derer, S, Klausz, K, Rosskopf, S, Wirt, T, Rösner, T, Otte, A, Cappuzzello, E & Peipp, M 2018, Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity. in D Nevoltris & P Chames (eds), Antibody Engineering. vol. 1827, Methods in Molecular Biology, vol. 1827, Humana Press Inc., New York, NY, pp. 381-397. https://doi.org/10.1007/978-1-4939-8648-4_20

Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity. / Kellner, Christian; Derer, Stefanie; Klausz, Katja et al.
Antibody Engineering. ed. / Damien Nevoltris; Patrick Chames. Vol. 1827 New York, NY: Humana Press Inc., 2018. p. 381-397 (Methods in Molecular Biology; Vol. 1827).

Research output: Chapters in Books/Reports/Conference Proceedings › Chapter › peer-review

TY - CHAP

T1 - Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity

AU - Kellner, Christian

AU - Derer, Stefanie

AU - Klausz, Katja

AU - Rosskopf, Sophia

AU - Wirt, Tim

AU - Rösner, Thies

AU - Otte, Anna

AU - Cappuzzello, Elisa

AU - Peipp, Matthias

PY - 2018/9/9

Y1 - 2018/9/9

N2 - Monoclonal antibodies are established treatment options in cancer therapy. However, not all patients benefit from antibody therapy. Basic research and findings from clinical trials revealed that certain Fc-mediated effector mechanisms triggered by monoclonal antibodies are essential for efficient antitumor activity. Today, next-generation monoclonal antibodies can be designed displaying tailor-made improved effector functions. The introduction of Fc-engineering technologies offers the potential to fine-tune Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDC). Fc-engineered antibodies hopefully will overcome some limitations of current forms of antibody therapy.

AB - Monoclonal antibodies are established treatment options in cancer therapy. However, not all patients benefit from antibody therapy. Basic research and findings from clinical trials revealed that certain Fc-mediated effector mechanisms triggered by monoclonal antibodies are essential for efficient antitumor activity. Today, next-generation monoclonal antibodies can be designed displaying tailor-made improved effector functions. The introduction of Fc-engineering technologies offers the potential to fine-tune Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDC). Fc-engineered antibodies hopefully will overcome some limitations of current forms of antibody therapy.

UR - http://www.scopus.com/inward/record.url?scp=85053074662&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-8648-4_20

DO - 10.1007/978-1-4939-8648-4_20

M3 - Chapter

C2 - 30196508

AN - SCOPUS:85053074662

SN - 978-1-4939-8647-7

VL - 1827

T3 - Methods in Molecular Biology

SP - 381

EP - 397

BT - Antibody Engineering

A2 - Nevoltris, Damien

A2 - Chames, Patrick

PB - Humana Press Inc.

CY - New York, NY

ER -

Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this